November 22, 2011—The Health Resources and Services Administration’s (HRSA) Office of Pharmacy Affairs (OPA) issued three documents late yesterday clarifying its policies in three areas: manufacturer audits of 340B covered entities, procedures for allocating 340B-priced drugs in short supply, and the office’s “penny pricing” policy when the statutory 340B ceiling price formula yields a zero or negative price.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)